Cytokinetics (NASDAQ:CYTK) vs. Taysha Gene Therapies (NASDAQ:TSHA) Financial Analysis

Cytokinetics (NASDAQ:CYTK) and Taysha Gene Therapies (NASDAQ:TSHA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Volatility & Risk

Cytokinetics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Cytokinetics and Taysha Gene Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Institutional and Insider Ownership

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by company insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Cytokinetics and Taysha Gene Therapies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	104.26	-$784.96 million	($7.22)	-10.22
Taysha Gene Therapies	$9.77 million	167.42	-$109.00 million	($0.42)	-11.95

Taysha Gene Therapies has lower revenue, but higher earnings than Cytokinetics. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Cytokinetics and Taysha Gene Therapies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	18	0	2.85
Taysha Gene Therapies	1	0	11	2	3.00

Cytokinetics presently has a consensus target price of $103.37, suggesting a potential upside of 40.12%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 154.37%. Given Taysha Gene Therapies’ stronger consensus rating and higher probable upside, analysts plainly believe Taysha Gene Therapies is more favorable than Cytokinetics.

Summary

Taysha Gene Therapies beats Cytokinetics on 11 of the 15 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.